News

Call to Action – NIH Technology Accelerator Challenge for Maternal Health – up to $1 Million in Cash Prizes!

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is proud to announce the launch of the NIH Technology Accelerator Challenge for Maternal Health (NTAC: Maternal Health) in conjunction with the White House Maternal Health Day of Action. 

NTAC: Maternal Health is offering up to $1,000,000 in cash prizes to reward the development of low-cost, point-of-care molecular, cellular, and/or metabolic sensing and diagnostic technologies to guide rapid clinical decision-making, improve patient outcomes, and ultimately prevent maternal morbidity and mortality. More broadly, the NTAC series of prize competition’s goals are to stimulate the design of new diagnostic technologies to transform public and global health and accelerate the full development of those products urgently needed for use in low-resource settings. Device prototypes submitted to NTAC: Maternal Health should be capable of full integration with digital health platforms and be able to diagnose at least two pregnancy-associated conditions, including infections, hypertensive disease, hemorrhage, or placental issues. Complete challenge details can be found at https://www.nibib.nih.gov/research-program/NIH-Technology-Accelerator-Challenge-Maternal-Health-Announcement .

Participants in NTAC: Maternal Health will compete for the first-place prize of up to $500,000, a second-place prize of up to $300,000, and a third-place prize of up to $150,000, with the potential for additional awards of $50,000 for semi-finalists as well as honorable mention recognitions. Additionally, the Bill & Melinda Gates Foundation is collaborating with NIH and will separately review winners and honorable mentions to consider them for follow-on support that may include grant funding and/or in-kind support in the form of consultations and partnerships for clinical data collection, software development, scale-up, and manufacturing. This Challenge is also co-sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH Office of Research on Women’s Health.

The Challenge sponsors will host an Informational Webinar for any interested participants on January 13, 2022, from 12:00 pm-1:00 pm ET. Participants wishing to compete in NTAC: Maternal Health must register for the Challenge by April 1, 2022, at https://venturewell.org/ntac/. Submissions will begin to be accepted on January 5, 2022, and must be submitted by April 22, 2022. In case of any questions, send an email to NIBIBChallenge@mail.nih.gov .

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation